Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

The study achieved its primary endpoint in the estrogen receptor 1-mutant (ESR1m) patient population. This company is expected to post quarterly loss of $0.85 per share in its upcoming report ...

The study achieved its primary endpoint in the estrogen receptor one-mutant (ESR1m) patient population. It showed a statistically significant and clinically meaningful improvement in progression ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...

Pipeline and key clinical candidates for these companies: Arvinas is a clinical-stage biotechnology company that says it is “dedicated to improving the lives of patients suffering from ...